National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 38920-38921 [2017-17280]
Download as PDF
<![CDATA[
38920
Federal Register / Vol. 82, No. 157 / Wednesday, August 16, 2017 / Notices
awards (currently active grants,
cooperative agreements, and
procurement contracts) greater than
$10,000,000 for any period of time
during the period of performance of an
award/project.
Mandatory Disclosure Requirements
As required by 2 CFR part 200 of the
Uniform Guidance, and the HHS
implementing regulations at 45 CFR part
75, effective January 1, 2016, the IHS
must require a non-federal entity or an
applicant for a federal award to disclose,
in a timely manner, in writing to the
IHS or pass-through entity all violations
of federal criminal law involving fraud,
bribery, or gratuity violations
potentially affecting the federal award.
Submission is required for all
applicants and recipients, in writing, to
the IHS and to the HHS Office of
Inspector General all information
related to violations of federal criminal
law involving fraud, bribery, or gratuity
violations potentially affecting the
federal award. 45 CFR 75.113.
Disclosures must be sent in writing to:
U.S. Department of Health and Human
Services, Indian Health Service,
Division of Grants Management, ATTN:
Robert Tarwater, Director, 5600 Fishers
Lane, Mail Stop: 09E70.
Rockville, MD 20857
(Include ‘‘Mandatory Grant
Disclosures’’ in subject line)
Office: (301) 443–5204.
Fax: (301) 594–0899.
Email: Robert.Tarwater@ihs.gov.
asabaliauskas on DSKBBXCHB2PROD with NOTICES
AND
U.S. Department of Health and
Human Services, Office of Inspector
General, ATTN: Mandatory Grant
Disclosures, Intake Coordinator, 330
Independence Avenue SW., Cohen
Building, Room 5527, Washington, DC
20201, URL: https://oig.hhs.gov/fraud/
report-fraud/index.asp.
(Include ‘‘Mandatory Grant
Disclosures’’ in subject line)
Fax: (202) 205–0604 (Include
‘‘Mandatory Grant Disclosures’’ in
subject line) or
Email:
MandatoryGranteeDisclosures@
oig.hhs.gov
Failure to make required disclosures
can result in any of the remedies
described in 45 CFR 75.371 Remedies
for noncompliance, including
suspension or debarment (See 2 CFR
parts 180 & 376 and 31 U.S.C. 3321).
VII. Agency Contacts
1. Questions on the programmatic
issues may be directed to: Lisa C. Neel,
MPH, Public Health Advisor, Office of
Public Health Support, Division of
VerDate Sep<11>2014
18:33 Aug 15, 2017
Jkt 241001
Epidemiology & Disease Prevention,
Indian Health Service, 5600 Fishers
Lane, Mailstop: 09E17B, Rockville, MD
20857, Phone: (301) 443–4305, E-Mail:
Lisa.Neel@ihs.gov.
2. Questions on grants management
and fiscal matters may be directed to:
John Hoffman, Senior Grants
Management Specialist, IHS Division of
Grants Management, 5600 Fishers Lane,
Mailstop: 09E70, Rockville, MD 20857,
Phone: (301) 443–2116, E-Mail:
John.Hoffman@ihs.gov.
3. Questions on systems matters may
be directed to: Paul Gettys, Grant
Systems Coordinator, 5600 Fishers
Lane, Mail Stop: 09E70, Rockville, MD
20857, Phone: (301) 443–2114; or the
DGM main line (301) 443–5204, Fax:
(301) 594–0899, E-Mail: Paul.Gettys@
ihs.gov.
VIII. Other Information
The Public Health Service strongly
encourages all cooperative agreement
and contract recipients to provide a
smoke-free workplace and promote the
non-use of all tobacco products. In
addition, Public Law 103–227, the ProChildren Act of 1994, prohibits smoking
in certain facilities (or in some cases,
any portion of the facility) in which
regular or routine education, library,
day care, health care, or early childhood
development services are provided to
children. This is consistent with the
HHS mission to protect and advance the
physical and mental health of the
American people.
Dated: August 10, 2017.
Michael D. Weahkee,
RADM, Assistant Surgeon General, U.S.
Public Health Service, Acting Director, Indian
Health Service.
[FR Doc. 2017–17311 Filed 8–15–17; 8:45 am]
BILLING CODE 4160–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR–17–270:
NIDDK Biorepositories Sample Access.
Date: September 21, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Najma S. Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Multi-Center
Clinical Applications (PA–16–160).
Date: September 25, 2017.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Najma S. Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR–17–123:
NIDDK Biomarker R01s on Biorepository
Samples.
Date: September 27, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Najma S. Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR–15–068:
NIDDK Multi-Center Clinical Study
Implementation Planning Cooperative
Agreements (U34).
Date: September 28, 2017.
Time: 3:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
E:\FR\FM\16AUN1.SGM
16AUN1
Federal Register / Vol. 82, No. 157 / Wednesday, August 16, 2017 / Notices
Contact Person: Najma S. Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: August 10, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–17280 Filed 8–15–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, NCI
Clinical and Translational R21 and Omnibus
R03: SEP 3.
Date: September 25–26, 2017.
Time: 8:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Westin Arlington Gateway, 801
N. Glebe Road, Arlington, VA 22203.
Contact Person: Robert Stephen Coyne,
Ph.D., Scientific Review Officer, Research
Program Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W236, Bethesda, MD 20892–9750,
240–276–5120, coynes@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, R25
Education.
Date: September 27, 2017.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
VerDate Sep<11>2014
18:33 Aug 15, 2017
Jkt 241001
7W608, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Robert E. Bird, Ph.D.,
Scientific Review Officer, Research Program,
Review Branch Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W608,
Bethesda, MD, 20892–9750, 240–276–6344,
birdr@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, NCI
Program Project I.
Date: October 12–13, 2017.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Anita T. Tandle, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W248,
Bethesda, MD 20892–9750, 240–276–5007,
tandlea@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, SBIR Phase
II Bridge Awards.
Date: October 12, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W238, Rockville, MD 20850, (Telephone
Conference Call).
Contact Person: Jeffrey E. DeClue Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W238, Bethesda, MD 20892–
9750, 240–276–6371, decluej@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, NCI
Program Project II (P01).
Date: October 17–18, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville 1750
Rockville Pike Rockville, MD 20852.
Contact Person: Sanita Bharti, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W122,
Bethesda, MD 20892–9750, 240–276–5909,
sanitab@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, NCI
Program Project III (P01).
Date: October 17–18, 2017.
Time: 8:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Mukesh Kumar, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W618,
Bethesda, MD 20892–9750, 240–276–6611,
sanitab@mail.nih.gov.
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
38921
Name of Committee: National Cancer
Institute Special Emphasis Panel, Provocative
Questions: SEP 4.
Date: October 20, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Hasan Siddiqui, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W240, Bethesda, MD
20892–9750, 240–276–5122, hasan.siddiqui@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, NCI
Clinical and Translational R21 and Omnibus
R03: SEP–1.
Date: October 25–26, 2017.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Byeong-Chel Lee, Ph.D.,
Scientific Review Officer Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W238, Bethesda, MD 20892–9750
240–276–7755 byeong-chel.lee@nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group, NCI Clinical
and Translational R21 and Omnibus R03:
SEP–4.
Date: October 25–26, 2017.
Time: 6:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20892–9750.
Contact Person: Eduardo E. Chufan, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W254, Bethesda, MD 20892–
9750, 240–276–7975, chufanee@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, R01
Review Teleconference.
Date: October 31, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W608, Rockville, MD 20850, (Telephone
Conference Call).
Contact Person: Robert E. Bird, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W608,
Bethesda, MD 20892–9750, 240–276–6344,
birdr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
E:\FR\FM\16AUN1.SGM
16AUN1
]]>Agencies
[Federal Register Volume 82, Number 157 (Wednesday, August 16, 2017)]
[Notices]
[Pages 38920-38921]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-17280]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; PAR-17-270: NIDDK
Biorepositories Sample Access.
Date: September 21, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Najma S. Begum, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-8894, begumn@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Multi-Center Clinical
Applications (PA-16-160).
Date: September 25, 2017.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Najma S. Begum, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-8894, begumn@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; PAR-17-123: NIDDK
Biomarker R01s on Biorepository Samples.
Date: September 27, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Najma S. Begum, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-8894, begumn@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; PAR-15-068: NIDDK Multi-
Center Clinical Study Implementation Planning Cooperative Agreements
(U34).
Date: September 28, 2017.
Time: 3:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
[[Page 38921]]
Contact Person: Najma S. Begum, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7349, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-8894, begumn@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: August 10, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-17280 Filed 8-15-17; 8:45 am]
BILLING CODE 4140-01-P
